Cardiology medical device maker AtriCure (NASDAQ:ATRC) expects to receive U.S. regulatory clearance for a new cryoablation system by the end of next quarter.
The company’s cryoICE BOX system would use extreme cold to freeze cardiac tissue in order to correct abnormal electrical signals that cause heart arrhythmia.
The system was launched during the second quarter in Europe and the company expects the new innovative medical device to be available for “full commercial release” in the U.S. and Europe during the third quarter, according to a statement announcing the company’s second-quarter earnings.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
For its second quarter, AtriCure reported a loss of 6 cents per share, 1 cent worse than Wall Street analysts had expected. Revenue grew 18 percent to $16.8 million, which slightly exceeded Wall Street’s expectations.
The sales growth was driven in part by international markets. International revenue hit $4.1 million, up 78 percent from the year-ago quarter.
Sales for the company’s AtriClip system were $1.3 million. The device is a clip used during heart surgery to exclude the left atrial appendage.
